Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience-Reference-Cited by-同舟云学术

Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience

Published:2009-01 Issue:1 Volume:20 Page:27-33
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Olmos D.,Arkenau H.-T.,Ang J.E.,Ledaki I.,Attard G.,Carden C.P.,Reid A.H.M.,A'Hern R.,Fong P.C.,Oomen N.B.,Molife R.,Dearnaley D.,Parker C.,Terstappen L.W.M.M.,de Bono J.S.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/20/1/27/307931/mdn544.pdf

Reference19 articles.

1. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group;Bubley;J Clin Oncol,1999

2. New guidelines to evaluate the response to treatment in solid tumors;Therasse;J Natl Cancer Inst,2000

3. Prostate cancer clinical trial end points: “RECIST”ing a step backwards;Scher;Clin Cancer Res,2005

4. Clinical trials in relapsed prostate cancer: defining the target;Scher;J Natl Cancer Inst,1996

5. Is prostate specific antigen a valid surrogate end-point for survival in hormonally treated patients with metastatic prostate cancer;Collette;J Clin Oncol,2005

Cited by 214 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic value of circulating tumor cells in oligorecurrent hormone‐sensitive prostate cancer patients undergoing stereotactic body radiation therapy;The Prostate;2024-09-06

2. STIM1, ORAI1, and KDM2B in circulating tumor cells (CTCs) isolated from prostate cancer patients;Frontiers in Cell and Developmental Biology;2024-06-05

3. A Molecular Voyage: Multiomics Insights into Circulating Tumor Cells;Cancer Discovery;2024-06-03

4. Comprehensive Analysis of CXCR4, JUNB, and PD-L1 Expression in Circulating Tumor Cells (CTCs) from Prostate Cancer Patients;Cells;2024-05-03

5. Circulating Biomarkers Predictive of Treatment Response in Patients with Hormone-sensitive or Castration-resistant Metastatic Prostate Cancer: A Systematic Review;European Urology Oncology;2024-05